FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:1893-1902 November 8, 2007 Number 19 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Stevenson, D. K. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Methylxanthine therapy is commonly used for apnea of prematurity but in the absence of adequate data on its efficacy and safety. It is uncertain whether methylxanthines have long-term effects on neurodevelopment and growth.

Methods We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed. The primary outcome was a composite of death, cerebral palsy, cognitive delay (defined as a Mental Development Index score of <85 on the Bayley Scales of Infant Development), deafness, or blindness at a corrected age of 18 to 21 months.

Results Of the 937 infants assigned to caffeine for whom adequate data on the primary outcome were available, 377 (40.2%) died or survived with a neurodevelopmental disability, as compared with 431 of the 932 infants (46.2%) assigned to placebo for whom adequate data on the primary outcome were available (odds ratio adjusted for center, 0.77; 95% confidence interval [CI], 0.64 to 0.93; P=0.008). Treatment with caffeine as compared with placebo reduced the incidence of cerebral palsy (4.4% vs. 7.3%; adjusted odds ratio, 0.58; 95% CI, 0.39 to 0.87; P=0.009) and of cognitive delay (33.8% vs. 38.3%; adjusted odds ratio, 0.81; 95% CI, 0.66 to 0.99; P=0.04). The rates of death, deafness, and blindness and the mean percentiles for height, weight, and head circumference at follow-up did not differ significantly between the two groups.

Conclusions Caffeine therapy for apnea of prematurity improves the rate of survival without neurodevelopmental disability at 18 to 21 months in infants with very low birth weight. (ClinicalTrials.gov number, NCT00182312 [ClinicalTrials.gov] .)

Source Information

From the Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada (B.S., R.S.R., A.O.); the Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Australia (P.D., L.W.D.); the Department of Pediatrics, McGill University, Montreal (K.J.B.); the Department of Pediatrics, University of Toronto, Toronto (A.O.); the Department of Pediatrics, University of British Columbia, Vancouver, Canada (A.S.); and the Department of Pediatrics, James Cook University Hospital, Middlesbrough, United Kingdom (W.T.).

Address reprint requests to Dr. Schmidt at the Neonatal Trials Group, Henderson Research Centre, G Wing, 2nd Fl., Rm. 217, 711 Concession St., Hamilton, ON L8V 1C3, Canada, or at schmidt{at}mcmaster.ca or barbara.schmidt{at}uphs.upenn.edu.

Full Text of this Article

This article has been cited by other articles:

• Funk, G. D. (2009). Losing sleep over the caffeination of prematurity. J. Physiol. 587: 5299-5300 [Full Text]  
• Montandon, G., Horner, R. L., Kinkead, R., Bairam, A. (2009). Caffeine in the neonatal period induces long-lasting changes in sleep and breathing in adult rats. J. Physiol. 587: 5493-5507 [Abstract] [Full Text]  
• McGuire, W., Fowlie, P. W. (2009). Bridging the gaps: getting evidence into practice. CMAJ 181: 457-458 [Full Text]  
• Martin, R. J., Wilson, C. G. (2009). What to do about apnea of prematurity?. J. Appl. Physiol. 107: 1015-1016 [Full Text]  
• Lenney, W., Boner, A. L., Bont, L., Bush, A., Carlsen, K-H., Eber, E., Fauroux, B., Gotz, M., Greenough, A., Grigg, J., Hull, J., Kimpen, J., Sanchez Luna, M., de Benedictis, F. M. (2009). Medicines used in respiratory diseases only seen in children. Eur Respir J 34: 531-551 [Abstract] [Full Text]  
• Laughon, M., O'Shea, M. T., Allred, E. N., Bose, C., Kuban, K., Van Marter, L. J., Ehrenkranz, R. A., Leviton, A., for the ELGAN Study Investigators, (2009). Chronic Lung Disease and Developmental Delay at 2 Years of Age in Children Born Before 28 Weeks' Gestation. Pediatrics 124: 637-648 [Abstract] [Full Text]  
• Yeaney, N. K, Murdoch, E. M, Lees, C. C (2009). The extremely premature neonate: anticipating and managing care. BMJ 338: b2325-b2325 [Full Text]  
• Bhandari, A., Bhandari, V. (2009). Pitfalls, Problems, and Progress in Bronchopulmonary Dysplasia. Pediatrics 123: 1562-1573 [Abstract] [Full Text]  
• Robertson, C. M. T., Howarth, T. M., Bork, D. L. R., Dinu, I. A. (2009). Permanent Bilateral Sensory and Neural Hearing Loss of Children After Neonatal Intensive Care Because of Extreme Prematurity: A Thirty-Year Study. Pediatrics 123: e797-e807 [Abstract] [Full Text]  
• Doyle, L. W., Saigal, S. (2009). Long-term Outcomes of Very Preterm or Tiny Infants. NeoReviews 10: e130-e137 [Abstract] [Full Text]  
• Whyte, R. K., Kirpalani, H., Asztalos, E. V., Andersen, C., Blajchman, M., Heddle, N., LaCorte, M., Robertson, C. M. T., Clarke, M. C., Vincer, M. J., Doyle, L. W., Roberts, R. S., for the PINTOS Study Group, (2009). Neurodevelopmental Outcome of Extremely Low Birth Weight Infants Randomly Assigned to Restrictive or Liberal Hemoglobin Thresholds for Blood Transfusion. Pediatrics 123: 207-213 [Abstract] [Full Text]  
• Chalmers, I. (2008). Confronting therapeutic ignorance. BMJ 337: a841-a841 [Full Text]  
• Eichenwald, E. C., Stark, A. R. (2008). Management and Outcomes of Very Low Birth Weight. NEJM 358: 1700-1711 [Full Text]  
• de Visser, Y. P., Walther, F. J., Laghmani, E. H., van Wijngaarden, S., Nieuwland, K., Wagenaar, G. T. M. (2008). Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury. Eur Respir J 31: 633-644 [Abstract] [Full Text]  
• Stevenson, D. K. (2007). On the Caffeination of Prematurity. NEJM 357: 1967-1968 [Full Text]  
• (2007). Efficacy and Safety of Caffeine for Apnea of Prematurity. JWatch Pediatrics 2007: 1-1 [Full Text]